| 替吉奥为基础的化疗在消化道肿瘤中安全性的观察和分析 |
| |
| 引用本文： | 黄镜,王向玲,周一,周爱萍,陶云霞,王金万. 替吉奥为基础的化疗在消化道肿瘤中安全性的观察和分析[J]. 癌症进展, 2011, 9(6): 707-710,717 |
| |
| 作者姓名： | 黄镜 王向玲 周一 周爱萍 陶云霞 王金万 |
| |
| 作者单位： | 1. 中国医学科学院北京协和医学院肿瘤医院内科,北京,100021
2. 山东大学齐鲁医院肿瘤防治中心化疗科,济南,250012 |
| |
| 摘 要： | 目的 观察不同剂量替吉奥在消化道肿瘤患者中的耐受性和近期疗效.方法 44例消化道肿瘤患者,15例给予替吉奥80mg/ (m2 ·d),29例给予替吉奥50～70mg/ (m2 ·d)为基础的联合化疗方案,观察其不良反应及近期疗效.结果 所有病例中9例(20.45％)发生Ⅲ/Ⅳ级血液学毒性,7例(15.90％)发生Ⅲ/Ⅳ...
|
| 关 键 词： | 替吉奥 化疗 毒副反应 |
Observation and analysis of safety in gastrointestinal cancer patients treated with S- 1 -based chemotherapy |
| |
| Huang Jing,Wang Xiangling,Zhou Yi,Zhou Aipin,Tao Yunxia,Wang Jinwan. Observation and analysis of safety in gastrointestinal cancer patients treated with S- 1 -based chemotherapy[J]. Oncology Progress, 2011, 9(6): 707-710,717 |
| |
| Authors: | Huang Jing Wang Xiangling Zhou Yi Zhou Aipin Tao Yunxia Wang Jinwan |
| |
| Affiliation: | 1Department of Medical Oncology,Cancer Hospital,Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing 100021,China 2Department of Chemotherapy,Qilu Hospital,Shangdong Medical College,Jinan 250012,China |
| |
| Abstract: | Objective To investigate the short-term efficacy and safety of S-1-based chemotherapy in the treatment of gastrointestinal（GI） cancer at different doses.Methods A total of 44 patients with GI cancer were treated with S-1-based chemotherapy.The doses of S-1 were 80mg/m2/d in 15 patients and 50-70mg/m2/d in the other 29 patients.The side effects were carefully observed and the response rates were evaluated in time.Results The grade 3/4 hematological toxicities were seen in 9（20.45%） patients.The incidence rate was 33.33% in patients treated with high dose and 13.97% in patients with low dose.The grade 3/4 gastrointestinal toxicities were seen in 7（15.90%） patients.The incidence rates were 46.67% in high dose group and 0% in low dose group.The grade 3/4 anorexia was seen in 6（40.00%） patients in high dose group and 0 in low dose group.Compared with low dose group,the high dose group suffered higher GI toxicities.Meanwhile,the response rate were 57.14% in high dose group and 60.00% in low dose group,while S-1 was used in patients with gastric cancer and gastroesophageal junction cancer that were assessable for the response.Conclusion S-1 is well-tolerated at the dose of 50-70mg/m2/d in patients with GI cancer.S-1 given at the dose of 50-70mg/m2/d can achieve promising response rate and mild toxicity,and might be recommended in combined chemotherapy in GI cancer. |
| |
| Keywords: | S-1 chemotherapy toxicity |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
